Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study on Efficacy Evaluation of Ripertamab in the Treatment of Neuromyelitis Optica Spectrum Disorders

NCT07685678 is registered in ClinicalTrials.gov with Zhongming Qiu as lead sponsor.

NCT NCT07685678
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07685678 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Study on Efficacy Evaluation of Ripertamab in the Treatment of Neuromyelitis Optica Spectrum Disorders
Lead sponsor
Zhongming Qiu
Phase
Phase 1/2
Overall status
Not yet recruiting
Start date
September 30, 2026
Completion date
June 30, 2030
Enrollment
20 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

neuromyelitis optica spectrum disease (nmosd), ripertamab